samedan logo
 
 
 
spacer
home > ebr > autumn 2017 > enhanced effects
PUBLICATIONS
European Biopharmaceutical Review

Enhanced Effects

Cellular therapies – such as treatment with mesenchymal stem cells (MSCs) or, recently, with genetically adapted T-autologous (Ta) cells – are coming of age and have exhibited their efficacy for selected indications in numerous preclinical trials. Many have received first approvals or are likely to in the near future. MSCs have been approved for selected indications in Canada as well as New Zealand, and at least one chimeric antigen receptor (CAR) T-cell product has gained a unanimous positive review by the FDA advisory committee.

The cross-section of medical devices and cellular therapies has been explored and utilised for some time; for example, cells have been embedded in collagenous foams to secure their location, or catheters have been employed to facilitate targeted delivery of cells.

For biologics and small molecules, this cross-section is perhaps not as clearly visible, yet it has transpired that combinations may yield massive improvements, as demonstrated in preclinical studies. Hence, this appears to be an opportunity worthy of exploration due to its benefits as well as its practical, quality and regulatory implications.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Christian van den Bos founded Mares Ltd in 2007 to accelerate the development of regenerative medicinal products and currently serves as its Managing Director. He underwent postdoctoral training at Cold Spring Harbor Laboratories, US, and earned a PhD at the University of Münster, Germany, as well as an MSc at the University of Oxford, UK.
spacer
Dr Christian van den Bos
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera wins Pharmapack Award in Connected Devices and Wearables category with its body injector platform Symbioze

Symbioze, the smart, high volume and sustainable on-body injector platform developed by Nemera, wins the ‘Connected Devices and Wearables’ Award at Pharmapack 2021 On October 12th, during the Pharmapack Awards Ceremony, a team of industry experts awarded Symbioze, Nemera’s large-volume on-body injector, with the Pharmapack Award in the “Connected Devices and Wearables” category.
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement